Toronto, Ontario, June 04, 2020 (GLOBE NEWSWIRE) -- Toronto Innovation Acceleration Partners (TIAP) announced today the launch of a new LAB150 project aimed at developing a novel therapeutic agent for…
TORONTO, May 12, 2020 (GLOBE NEWSWIRE) -- Toronto Innovation Acceleration Partners (TIAP), Evotec SE and AmorChem II Fund L.P. (AmorChem) are pleased to announce a $1.75M investment into a drug…
Toronto, ON, June 11, 2019 (GLOBE NEWSWIRE) -- It is estimated that 5% of the global population is affected by Major Depressive Disorder (MDD) at any given time. While there…
Toronto, ON, Feb. 27, 2019 (GLOBE NEWSWIRE) -- MaRS Innovation announced today the concurrent launch of two new LAB150 projects. These projects build on breakthroughs in disease-focused scientific research by…
Toronto, ON, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Fibrocor Therapeutics, a privately held Canadian company, and Galapagos NV, a Belgo-Dutch pharmaceutical research company, have announced the formation of a partnership…
Toronto, Nov. 28, 2017 (GLOBE NEWSWIRE) -- Fibrocor Therapeutics (Fibrocor) announced today that Mark Steedman has been appointed as its first president and CEO, and will serve as a member of…
Toronto, Sept. 14, 2017 (GLOBE NEWSWIRE) -- MaRS Innovation (“MI”) and Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced the launch of “LAB150”. This transformational Toronto-based partnership…
Schwartz Reisman Innovation Campus, West Tower
108 College Street, Suite 530
Toronto, ON M5G 0C6
info@tiap.ca